The Nasdaq Biotech Index (NBI) gave back nearly half of the year’s gains from April 23rd to April 30th. Thus, a bounce is clearly in the offing and is one to watch carefully.  By the same token if Friday’s (May 1) bounce fizzles in the not too distant future, we… Read More

Just when people were starting to wonder if tech stocks could go much higher, they proved that they could – and with a vengeance. Last week was every tech stock investor’s dream, with a wide variety of companies benefiting from euphoria over better than expected earnings reports from Amazon.com (up… Read More

SolarWinds has nothing to do with solar energy, but it is a shining example of how a strategically sound acquisition strategy can add lots of value. Read More

Just as we believe innogration is the key to long term success for every tech company, so too do we feel it should be practiced by this publication so that our subscribers remain ahead of the curve. As you know, innogration consists of two critical components: innovation, which is achieved… Read More

I am adding Splunk to the Next Wave Portfolio because its solutions are increasingly being deployed across a variety of use cases— including traditional business intelligence (BI) functions—putting the company on a solid path to eventually reach $1 billion in annual revenue. Read More

These two biotech stocks offer a two-for-one proposition, which is a rare find in this sector. Read More